(WEX) Wex - Overview
Stock: Fleet Cards, Corporate Payments, Benefits Software
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 35.0% |
| Relative Tail Risk | -10.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.21 |
| Alpha | -36.19 |
| Character TTM | |
|---|---|
| Beta | 1.489 |
| Beta Downside | 1.565 |
| Drawdowns 3y | |
|---|---|
| Max DD | 53.15% |
| CAGR/Max DD | -0.14 |
Description: WEX Wex January 09, 2026
WEX Inc. (NYSE: WEX) runs a diversified commerce platform that spans three primary segments: Mobility, Corporate Payments, and Benefits Solutions. The Mobility segment delivers fleet-vehicle payment processing, account-management services, and analytics to commercial fleets and government agencies, leveraging both direct sales and co-branded/private-label partnerships. Corporate Payments offers embedded payment capabilities, accounts-payable automation, and spend-management tools to customers in travel, fintech, insurance, consumer-bill-pay, and media verticals. Benefits Solutions provides a SaaS platform for consumer-directed health benefits-including HSAs, HSAs, and COBRA administration-served through third-party administrators, payroll providers, and health plans.
Based on the FY 2023 earnings release, WEX generated $2.0 billion in revenue, with the Mobility segment contributing roughly 55 % and posting a 7 % year-over-year growth rate, driven by increasing demand for electric-vehicle fleet financing and higher transaction volumes. The Corporate Payments unit grew 9 % YoY, reflecting broader corporate spend-management trends and the acceleration of digital invoicing post-COVID-19. Benefits Solutions, while smaller (≈ 15 % of total revenue), posted a 12 % increase, underscoring the continued shift toward consumer-direct health accounts as employers seek cost-containment. Key economic drivers include corporate capital-expenditure cycles, regulatory changes in healthcare benefits (e.g., HSA contribution limits), and the macro-trend toward embedded finance in non-financial industries.
For a deeper, data-driven look at how these trends translate into valuation metrics, you might explore the analytics available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 283.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 1.23 > 1.0 |
| NWC/Revenue: 17.61% < 20% (prev 14.74%; Δ 2.87% < -1%) |
| CFO/TA 0.06 > 3% & CFO 798.0m > Net Income 283.8m |
| Net Debt (4.21b) to EBITDA (916.3m): 4.60 < 3 |
| Current Ratio: 1.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (34.8m) vs 12m ago -12.56% < -2% |
| Gross Margin: 59.06% > 18% (prev 0.61%; Δ 5845 % > 0.5%) |
| Asset Turnover: 18.49% > 50% (prev 19.02%; Δ -0.53% > 0%) |
| Interest Coverage Ratio: 2.63 > 6 (EBITDA TTM 916.3m / Interest Expense TTM 239.2m) |
Altman Z'' 1.19
| A: 0.03 (Total Current Assets 9.72b - Total Current Liabilities 9.25b) / Total Assets 14.43b |
| B: 0.16 (Retained Earnings 2.29b / Total Assets 14.43b) |
| C: 0.04 (EBIT TTM 630.0m / Avg Total Assets 14.20b) |
| D: 0.16 (Book Value of Equity 2.15b / Total Liabilities 13.31b) |
| Altman-Z'' Score: 1.19 = BB |
Beneish M -3.06
| DSRI: 1.02 (Receivables 3.82b/3.77b, Revenue 2.62b/2.65b) |
| GMI: 1.03 (GM 59.06% / 60.98%) |
| AQI: 0.94 (AQ_t 0.31 / AQ_t-1 0.33) |
| SGI: 0.99 (Revenue 2.62b / 2.65b) |
| TATA: -0.04 (NI 283.8m - CFO 798.0m) / TA 14.43b) |
| Beneish M-Score: -3.06 (Cap -4..+1) = AA |
What is the price of WEX shares?
Over the past week, the price has changed by +3.28%, over one month by +4.72%, over three months by +9.76% and over the past year by +4.62%.
Is WEX a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 13
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the WEX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 173.6 | 9.2% |
| Analysts Target Price | 173.6 | 9.2% |
| ValueRay Target Price | 167.5 | 5.4% |
WEX Fundamental Data Overview February 05, 2026
P/E Forward = 8.6881
P/S = 1.885
P/B = 4.6947
P/EG = 1.4479
Revenue TTM = 2.62b USD
EBIT TTM = 630.0m USD
EBITDA TTM = 916.3m USD
Long Term Debt = 3.72b USD (from longTermDebt, last quarter)
Short Term Debt = 1.31b USD (from shortTermDebt, last quarter)
Debt = 5.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.21b USD (from netDebt column, last quarter)
Enterprise Value = 9.16b USD (4.95b + Debt 5.03b - CCE 812.9m)
Interest Coverage Ratio = 2.63 (Ebit TTM 630.0m / Interest Expense TTM 239.2m)
EV/FCF = 14.25x (Enterprise Value 9.16b / FCF TTM 642.6m)
FCF Yield = 7.02% (FCF TTM 642.6m / Enterprise Value 9.16b)
FCF Margin = 24.48% (FCF TTM 642.6m / Revenue TTM 2.62b)
Net Margin = 10.81% (Net Income TTM 283.8m / Revenue TTM 2.62b)
Gross Margin = 59.06% ((Revenue TTM 2.62b - Cost of Revenue TTM 1.07b) / Revenue TTM)
Gross Margin QoQ = 60.35% (prev 58.64%)
Tobins Q-Ratio = 0.63 (Enterprise Value 9.16b / Total Assets 14.43b)
Interest Expense / Debt = 1.27% (Interest Expense 63.8m / Debt 5.03b)
Taxrate = 31.10% (36.2m / 116.4m)
NOPAT = 434.1m (EBIT 630.0m * (1 - 31.10%))
Current Ratio = 1.05 (Total Current Assets 9.72b / Total Current Liabilities 9.25b)
Debt / Equity = 4.49 (Debt 5.03b / totalStockholderEquity, last quarter 1.12b)
Debt / EBITDA = 4.60 (Net Debt 4.21b / EBITDA 916.3m)
Debt / FCF = 6.56 (Net Debt 4.21b / FCF TTM 642.6m)
Total Stockholder Equity = 1.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.00% (Net Income 283.8m / Total Assets 14.43b)
RoE = 25.82% (Net Income TTM 283.8m / Total Stockholder Equity 1.10b)
RoCE = 13.08% (EBIT 630.0m / Capital Employed (Equity 1.10b + L.T.Debt 3.72b))
RoIC = 6.99% (NOPAT 434.1m / Invested Capital 6.21b)
WACC = 6.10% (E(4.95b)/V(9.97b) * Re(11.40%) + D(5.03b)/V(9.97b) * Rd(1.27%) * (1-Tc(0.31)))
Discount Rate = 11.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -8.87%
[DCF Debug] Terminal Value 87.53% ; FCFF base≈565.3m ; Y1≈682.3m ; Y5≈1.11b
Fair Price DCF = 759.0 (EV 30.24b - Net Debt 4.21b = Equity 26.03b / Shares 34.3m; r=6.10% [WACC]; 5y FCF grow 22.11% → 2.90% )
EPS Correlation: -32.80 | EPS CAGR: -44.56% | SUE: -4.0 | # QB: 0
Revenue Correlation: 79.61 | Revenue CAGR: 9.19% | SUE: 0.87 | # QB: 1
EPS next Quarter (2026-03-31): EPS=4.01 | Chg30d=+0.014 | Revisions Net=+0 | Analysts=12
EPS next Year (2026-12-31): EPS=17.61 | Chg30d=-0.038 | Revisions Net=+1 | Growth EPS=+10.4% | Growth Revenue=+4.0%